Antidepressive Agents, Fluoxetine, Major Depressive Disorder, Pharmacogenetics, Venlafaxine
Conditions
Keywords
Major Depressive Disorder, Antidepressants, Pharmacogenetics, venlafaxine, fluoxetine
Brief summary
The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.
Interventions
DRUGVenlafaxine
The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
DRUGFluoxetine
The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
Sponsors
Department of Health, Executive Yuan, R.O.C. (Taiwan)
National Cheng-Kung University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age: 16-65 years old * Signed informed consent by patient or legal representative * Hamilton Rating Scale for Depression (HDRS) scores ≥ 16 * A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry
Exclusion criteria
* monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study * A DSM-IV diagnosis of substance abuse within the past three months * An organic mental disease, mental retardation or dementia * A serious surgical condition or physical illness * Patients who were pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Rating Scale (HDRS) | baseline |
Secondary
| Measure | Time frame |
|---|---|
| fasting blood glucose, lipid profiles | baseline |
| C-reactive Protein and IL-6 | baseline |
Countries
Taiwan
Outcome results
None listed